Cullinan Oncology Inc

+0.09 (+0.70%)
Products, Strategic Combinations

Cullinan Oncology And Taiho Pharmaceutical Complete Agreement For Strategic Collaboration To Jointly Develop And Commercialize Cln-081/Tas6417

Published: 06/23/2022 12:33 GMT
Cullinan Oncology Inc (CGEM) - Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize Cln-081/tas6417.
Cullinan Oncology - Gets Upfront Cash Payment of $275 Million, With Potential to Get Up to an Additional $130 Million in Regulatory-based Milestone Payments.
Cullinan Oncology Inc - Taiho Obtains Exclusive Global Rights to Cln-081/tas6417 Outside U.S.cullinan Oncology Inc - Taiho and Cullinan Oncology to Jointly Develop and Co-commercialize Cln-081/tas6417 in U.S.cullinan Oncology Inc - Cullinan Oncology and Taiho Will Equally Share Future Profits in U.S.cullinan Oncology Inc - Retains Option to Co-commercialize Cln-081/tas6417 in United States Together With Taiho Through Its U.S. Subsidiary.